A Phase 3 interventional study of Fluticasone Propionate in Nasal Polyps, sponsored by Optinose US Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.
Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.
Among the 83 studies in Nasal Polyps with a site in United States, this one is the 18th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2013, is one of 25 in phase 3, and was the 9th registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Japan, Puerto Rico
Ages 18+
GlaxoSmithKline · Sites in United States, Australia
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Airiver Medical, Inc. · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 27 · Phase 4 10
First in 2005; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Median enrollment 60 across the 71 interventional studies, 35 across the 12 observational. Of the 54 that completed or were terminated, 41 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 83 have an industry lead sponsor. The 10 most frequent:
Optinose US Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Optinose US Inc. has 4 studies filed under Nasal Polyps — fewer than ten, so there is no comparison to draw.
8 of the studies in Nasal Polyps with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07681973The Cleveland ClinicCognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training | 2026-12-31 |
| NCT07286201Polyganics BVEvaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF) | 2027-03 |
| NCT07599826Cedars-Sinai Medical CenterActive vs. Passive VR During Office-based ENT Procedures | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 83 studies in Nasal Polyps with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or without nasal polyps. The study consists of an up-to-7-day pretreatment phase followed a 12-month open-label treatment phase. The duration of each subject's participation is approximately 53 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men or women aged 18 years and older Women must
a history of chronic sinusitis with bilateral nasal polyposis determined by nasoendoscopy at screening visit OR a history of chronic sinusitis (without polyps) for equal to or greater than 12 weeks and currently experiencing 2 or more of the following symptoms, one of which MUST be either nasal blockage/congestion or nasal discharge (anterior and/or posterior nasal discharge):
reduction or loss of smell
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OPN-375 400 μg BID for 12 months
Drug: Fluticasone Propionate
Using Optinose Exhalation Delivery System
Also known as: OPN-375
Adverse Events
Patients with at least one Adverse Events
Time frame: 12 Months
Sinonasal Outcome Test 22 (SNOT-22) Total Score
Change from baseline to Month 3 \& Month 12 in SNOT-22 Total Score SNOT-22 is validated in large populations with chronic sinusitis with and without nasal polyps. The 22 questions are used to calculate a total score (the sum of all items) and 4 subscale scores. The 22 questions are divided among 4 subscales: Rhinologic, Ear and Facial Symptoms, Sleep Function, and Psychological Issues subscales. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as it can be
Time frame: Baseline, Month 3, Month 12
Lund-Mackay Total Score
Change from baseline to Month 3, Month 12, in Lund-Mackay Total Score Lund-Mackay Assessment of nasal cavity appearance, via nasoendoscopy, used to evaluate signs of edema, discharge, crusting, scarring/adhesions, and nasal polyps, with each sign rated on a 0 to 2 scale 0: None 2: Worse outcome
Time frame: Baseline, Month 3, Month 12
Patient Global Impression of Change (PGIC)
The PGIC took less than 1 minute to complete. Subjects answered question, "Since starting the study drug, how would you rate the change in your symptoms?" Patients may answer very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data listed below reports the total number of patients who answered very much improved, much improved, or minimally improved at the specified time.
Time frame: Baseline, Month 3, Month 12
Summed Bilateral Nasal Polyp Grading Scale Score
In subjects with nasal polyps, polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis: large polyps reaching below the lower inferior border of the inferior turbinate
Time frame: Baseline, Month 3, Month 12
Nasal Polyp Surgery Eligibility
Time frame: Baseline, Month 3, Month 12
| Milestone | OPN-375 400 μg |
|---|---|
| Started | 223 |
| Completed | 144 |
| Not completed | 79 |
| Withdrew: Adverse event | 21 |
| Withdrew: Lost to follow-up | 18 |
| Withdrew: Lack of efficacy | 6 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Withdrawal by subject | 25 |
| Withdrew: Became potentially child-bearing | 1 |
| Withdrew: Diagnoses of bilateral cateracts | 1 |
| Withdrew: Investigators discretion-noncompliant | 1 |
Patients with at least one Adverse Events
| Participants | OPN-375 400 μg |
|---|---|
| Adverse Events | 169 |
Change from baseline to Month 3 \& Month 12 in SNOT-22 Total Score SNOT-22 is validated in large populations with chronic sinusitis with and without nasal polyps. The 22 questions are used to calculate a total score (the sum of all items) and 4 subscale scores. The 22 questions are divided among 4 subscales: Rhinologic, Ear and Facial Symptoms, Sleep Function, and Psychological Issues subscales. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as it can be
| units on a scale | OPN-375 400 μg |
|---|---|
| Change from BL to Month 3, Pts With Polyps | -16.7 ± 15.39 |
| Change from BL to Month 3, Pts Without Polyps | -18.6 ± 20.06 |
| Change from BL to Month 12, Pts With Polyps | -21.5 ± 21.81 |
| Change from BL to Month 12, Pts Without Polyps | -21.1 ± 22.96 |
Change from baseline to Month 3, Month 12, in Lund-Mackay Total Score Lund-Mackay Assessment of nasal cavity appearance, via nasoendoscopy, used to evaluate signs of edema, discharge, crusting, scarring/adhesions, and nasal polyps, with each sign rated on a 0 to 2 scale 0: None 2: Worse outcome
| units on a scale | OPN-375 400 μg |
|---|---|
| Change from BL to Month 3, Pts With Polyps | -0.8 ± 1.35 |
| Change from BL to Month 3, Pts Without Polyps | -0.8 ± 1.21 |
| Change from BL to Month 12, Pts With Polyps | -0.7 ± 1.63 |
| Change from BL to Month 12, Pts Without Polyps | -0.8 ± 1.18 |
The PGIC took less than 1 minute to complete. Subjects answered question, "Since starting the study drug, how would you rate the change in your symptoms?" Patients may answer very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data listed below reports the total number of patients who answered very much improved, much improved, or minimally improved at the specified time.
| Participants | OPN-375 400 μg |
|---|---|
| Month 3, Pts With Polyps | 27 |
| Month 3, Patients Without Polyps | 151 |
| Month 12, Pts With Polyps | 22 |
| Month 12, Pts Without Polyps | 110 |
In subjects with nasal polyps, polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis: large polyps reaching below the lower inferior border of the inferior turbinate
| units on a scale | OPN-375 400 μg |
|---|---|
| Month 3 | 2.0 ± 1.81 |
| Month 12 | 1.3 ± 1.19 |
| Participants | OPN-375 400 μg |
|---|---|
| Month 3, Pts With Polyps | 5 |
| Month 3, Patients Without Polyps | 2 |
| Month 12, Pts With Polyps | 1 |
| Month 12, Pts Without Polyps | 3 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone | 0/223 (0%) | 0/223 (0%) | 169/223 (75.8%) |
| Event | Fluticasone |
|---|---|
| Nasal mucosal disorderRespiratory, thoracic and mediastinal disorders | 39/223 |
| Epistaxis Identified via Nasal EndoscopyRespiratory, thoracic and mediastinal disorders | 37/223 |
| Nasal Septum DisorderRespiratory, thoracic and mediastinal disorders | 32/223 |
| Acute SinusitisInfections and infestations | 31/223 |
| Spontaneously Reported EpistaxisRespiratory, thoracic and mediastinal disorders | 25/223 |
| Nasal Septum UlcerationRespiratory, thoracic and mediastinal disorders | 25/223 |
| HeadacheNervous system disorders | 21/223 |
| Upper Respiratory Tract InfectionInfections and infestations | 17/223 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 8/223 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/223 |
| Age, Continuous(years) | OPN-375 400 μg |
|---|---|
| Mean | 45.4 ± 12.62 |
| Sex: Female, Male(Participants) | OPN-375 400 μg |
|---|---|
| Female | 96 |
| Male | 127 |
| Race/Ethnicity, Customized(Participants) | OPN-375 400 μg |
|---|---|
| White | 175 |
| Black/African American | 45 |
| Asian | 2 |
| Other | 1 |
| Region of Enrollment(Participants) | OPN-375 400 μg |
|---|---|
| United States | 223 |
| Use of ICS treatment for polyps in past 10 years(Participants) | OPN-375 400 μg |
|---|---|
| Count of participants | 214 |
| Previous polyp removal surgery via polypectomy only(Participants) | OPN-375 400 μg |
|---|---|
| Count of participants | 11 |
| Previous sinus surgery for polyp removal or sinus surgery(Participants) | OPN-375 400 μg |
|---|---|
| Count of participants | 80 |
| Sinonasal Outcome Test 22 (SNOT-22) Total Score(units on a scale) | OPN-375 400 μg |
|---|---|
| Pts With Polyps | 41.9 ± 23.27 |
| Pts Without Polyps | 39.7 ± 21.72 |
3 further baseline measures are reported on the registry.
The record gives a start of Sep 2013, a primary completion of Aug 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2018, 2 years 5 months after primary completion. A results delay was requested in Jul 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Optinose US Inc.